Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1646 of 5804
-
New chemo cocktail shows promise against tough bile duct cancer
Disease control CompletedTo evaluate the following items in patients with locally advanced and metastatic biliary tract cancer receiving SLOG or GC treatment, Primary objective: 6-month progression-free survival rate Secondary objectives: Objective response rate Disease control rate (Objective response…
Phase: PHASE2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Targeted drug shows promise for kids with Tough-to-Treat cancers
Disease control OngoingThis phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or does not respond to treatment (refractory…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New hope for depression? accelerated brain zaps show promise
Symptom relief CompletedThis study evaluates the effectiveness of re-treatment using accelerated schedule of intermittent theta-burst stimulation for treatment-resistant depression. This is an open label study.
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jul 24, 2026 00:00 UTC
-
New oral drug shows promise for kids with gaucher disease
Disease control CompletedPrimary Objective: Evaluated the safety and pharmacokinetics of eliglustat in pediatric participants (≥2 to \<18 years old). Secondary Objective: Evaluated the efficacy of eliglustat and quality of life in pediatric participants (≥2 to \<18 years old).
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy drug nivolumab tested for rare thymus cancers
Disease control OngoingThe aim of the phase II Nivothym study is to collect data on activity and toxicity of nivolumab therapy in patients with thymic carcinoma or type B3 thymoma that previously received a first platinum-based chemotherapy.
Phase: PHASE2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
13-Year diabetes showdown: surgery vs. meds – which wins?
Knowledge-focused CompletedInitially, 4 teams of investigators conducted randomized controlled trials (RCT) at their own site to evaluate the effectiveness of bariatric surgery compared to medical/lifestyle management of type 2 diabetes. Each study followed subjects for a duration of about 1 - 3 years. Fol…
Sponsor: Ali Aminian • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Village birth helpers take on depression: a new hope for rural moms
Symptom relief CompletedEvidence from Low and Middle Income Countries has demonstrated the effectiveness of various psychosocial approaches for depression. However, there are no mental health specialists to deliver these interventions especially in rural African settings. This study aims at testing the …
Phase: NA • Sponsor: Africa Institute of Mental and Brain Health (AFRIMEB) • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
PET scans may outshine ejection fraction in predicting sudden cardiac death
Knowledge-focused OngoingSudden cardiac death continues to be a major contributor to mortality in patients with ischemic cardiomyopathy. While implantable defibrillators can prevent death from ventricular arrhythmias, our current approach to identify patients at highest risk primarily rests on demonstrat…
Sponsor: State University of New York at Buffalo • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Kidney disease drug trial halted midway
Disease control TerminatedThe primary objective of this study is to evaluate the effect of OMS721 on 24-hour urine protein excretion (UPE) in IgA nephropathy (IgAN) patients with high baseline proteinuria (high-risk proteinuria group; 24-hour UPE ≥ 2 g/day) assessed at 36 weeks from baseline.
Phase: PHASE3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could a common heart drug protect Preemies' lungs?
Disease control CompletedDescribe the safety of sildenafil in premature infants at risk of bronchopulmonary dysplasia and determine preliminary effectiveness and pharmacokinetics (PK) of sildenafil. Funding Source - FDA Office of Orphan Products Development (OOPD).
Phase: PHASE2 • Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug combo takes on deadly brain tumors
Disease control OngoingThis study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Three quick endoscopic checks may predict who still has reflux after surgery
Diagnosis CompletedThis single-center, two-phase cohort study aimed to develop and validate a simple endoscopic classification of fundoplication integrity after anti-reflux surgery (ARS - Nissen or Toupet fundoplication). Consecutive adult patients undergoing endoscopy, high-resolution manometry (H…
Sponsor: IRCCS Policlinico S. Donato • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
New study aims to stop breast cancer arm swelling before it starts
Disease control OngoingPrimary Objective * To compare the effectiveness of 2 treatment protocols for patients with breast cancer-related subclinical lymphedema identified through bioimpedance spectroscopy, L-dex scores Secondary Objectives * To determine the necessary duration of intervention to rev…
Phase: NA • Sponsor: Mercy Research • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Brain scans may unlock why antipsychotics work for some, not others
Knowledge-focused OngoingPsychosis is a heterogeneous disorder and present treatment only works for a limited number of patients. In order to identify new therapeutic targets, this study will longitudinally characterize the underlying pathologies in those with poor treatment response using complimentary …
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Could your own fat ease knee pain? new study tests it
Symptom relief CompletedThis is a non-surgical trial comparing the clinical and functional outcomes of patients with osteoarthritis treated with Intra-articular injection of Micro Fragmented Adipose Tissue versus conventional therapy of intra-articular injection of corticosteroid.
Phase: PHASE3 • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
New stent aims to keep heart arteries open longer
Disease control OngoingIt is a single arm clinical evaluation of safety and efficacy of the Medtronic Resolute Onyx™ zotarolimus-eluting coronary stent system in subjects who are eligible for percutaneous transluminal coronary angioplasty (PTCA) in de novo lesions amenable to treatment with Resolute On…
Phase: NA • Sponsor: Medtronic Vascular • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Universal DNA screening in endometrial cancer reveals hidden genetic risks
Knowledge-focused CompletedThis clinical trial studies universal screening for deoxyribonucleic acid (DNA) mismatch repair deficiency in patients with endometrial cancer, mutations in the genes responsible for Lynch syndrome (inherited forms of endometrial cancers) and other DNA changes that could help gui…
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
New shot aims to silence hepatitis b virus
Disease control CompletedThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-HBV in healthy adult volunteers and participants with hepatitis B virus (HBV).
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug cocktail shows promise for tough colon cancer
Disease control CompletedThis research study is designed to provide a better understanding of study drugs cetuximab (Erbitux®) and palbociclib when used in combination to treat patients with metastatic colon cancer.
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Week-Long nerve block after amputation may stop phantom pain and slash opioid use
Symptom relief OngoingWhen a limb is amputated, pain perceived in the part of the body that no longer exists often develops, called "phantom limb" pain. The exact reason that phantom limb pain occurs is unclear, but when a nerve is cut-as happens with an amputation-changes occur in the brain and spina…
Phase: PHASE4 • Sponsor: University of California, San Diego • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC